AU2017402210B2 - Monoclonal antibody against both IL-17A and IL-17F and use of the same - Google Patents

Monoclonal antibody against both IL-17A and IL-17F and use of the same Download PDF

Info

Publication number
AU2017402210B2
AU2017402210B2 AU2017402210A AU2017402210A AU2017402210B2 AU 2017402210 B2 AU2017402210 B2 AU 2017402210B2 AU 2017402210 A AU2017402210 A AU 2017402210A AU 2017402210 A AU2017402210 A AU 2017402210A AU 2017402210 B2 AU2017402210 B2 AU 2017402210B2
Authority
AU
Australia
Prior art keywords
antibody
seq
il17a
ser
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017402210A
Other languages
English (en)
Other versions
AU2017402210A1 (en
Inventor
Chen Dong
Li Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Kanova Biopharmaceutical Co Ltd
Original Assignee
Zhejiang Kanova Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Kanova Biopharmaceutical Co Ltd filed Critical Zhejiang Kanova Biopharmaceutical Co Ltd
Publication of AU2017402210A1 publication Critical patent/AU2017402210A1/en
Application granted granted Critical
Publication of AU2017402210B2 publication Critical patent/AU2017402210B2/en
Assigned to Zhejiang Kanova Biopharmaceutical Co., Ltd. reassignment Zhejiang Kanova Biopharmaceutical Co., Ltd. Request to Amend Deed and Register Assignors: Suzhou Kanova Biopharmaceutical Co., Ltd.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017402210A 2017-03-10 2017-03-10 Monoclonal antibody against both IL-17A and IL-17F and use of the same Active AU2017402210B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/076278 WO2018161340A1 (en) 2017-03-10 2017-03-10 Monoclonal antibody against both il-17a and il-17f and use of the same

Publications (2)

Publication Number Publication Date
AU2017402210A1 AU2017402210A1 (en) 2019-10-31
AU2017402210B2 true AU2017402210B2 (en) 2021-08-19

Family

ID=63448085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017402210A Active AU2017402210B2 (en) 2017-03-10 2017-03-10 Monoclonal antibody against both IL-17A and IL-17F and use of the same

Country Status (7)

Country Link
US (1) US10858427B2 (https=)
EP (1) EP3592771A4 (https=)
JP (1) JP6876156B2 (https=)
KR (1) KR102321861B1 (https=)
CN (1) CN110582512B (https=)
AU (1) AU2017402210B2 (https=)
WO (1) WO2018161340A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003329B (zh) * 2019-04-12 2022-09-27 深圳普瑞金生物药业股份有限公司 多肽、il17a/f单域抗体、核苷酸序列及试剂盒
US11827709B2 (en) * 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CN119301153A (zh) * 2022-06-29 2025-01-10 上海齐鲁制药研究中心有限公司 结合il-17a和il-17f的抗体分子及其应用
CN116063493B (zh) * 2022-07-22 2023-09-01 贵州省赛尔生物科技有限公司 包含抗体和间充质干细胞外泌体的药物组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106769A2 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
WO2012095662A1 (en) * 2011-01-14 2012-07-19 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1963368B3 (en) * 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
JP5116842B2 (ja) 2007-04-27 2013-01-09 ザイモジェネティクス， インコーポレイテッド ＩＬ−１７ＡおよびＩｌ−１７Ｆの両方に結合する抗体ならびにそれを使用する方法
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
RU2474588C2 (ru) * 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
MA33248B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Traitement de troubles résistant à l'insuline
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
US8945553B2 (en) 2012-05-22 2015-02-03 Bristol-Myers Squibb Company Bispecific antibodies to IL-23 and IL-17A/F
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
WO2014161570A1 (en) * 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
EP3027649B1 (en) * 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
CN106336459B (zh) * 2015-07-13 2020-12-08 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106769A2 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
WO2012095662A1 (en) * 2011-01-14 2012-07-19 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f

Also Published As

Publication number Publication date
AU2017402210A1 (en) 2019-10-31
KR20190128677A (ko) 2019-11-18
US10858427B2 (en) 2020-12-08
EP3592771A1 (en) 2020-01-15
CN110582512B (zh) 2022-08-30
US20200031919A1 (en) 2020-01-30
JP2020511159A (ja) 2020-04-16
JP6876156B2 (ja) 2021-05-26
WO2018161340A1 (en) 2018-09-13
CN110582512A (zh) 2019-12-17
KR102321861B1 (ko) 2021-11-05
EP3592771A4 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
JP6883591B2 (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用
CN111171150B (zh) 抗人tslp抗体及其用途
AU2017402210B2 (en) Monoclonal antibody against both IL-17A and IL-17F and use of the same
CN115433275B (zh) 抗胸腺基质淋巴细胞生成素（tslp）抗体及其用途
KR20200047606A (ko) Il-6r 항체와 이의 항원 결합 단편 및 의학적 용도
CN114920838A (zh) 一种抗il-17a的单域抗体及其用途
CA2913118A1 (en) Anti-tnf-.alpha./cxcl10 double-targeting antibody and use thereof
AU2018450414B2 (en) Anti-IL-25 antibodies and use thereof
CN118063607A (zh) 抗犬il-31抗体及其用途
JP7696291B2 (ja) 抗ｉｌ‐１７ａ抗体及びその適用
CN111699006B (zh) Il17抗体及其应用
CN110483640A (zh) 白介素-6r的人源化单克隆抗体、其编码基因及应用
JP6930778B2 (ja) 抗ヒトインターロイキン１７ａモノクローナル抗体およびその使用
CN113698484B (zh) 抗il-23r抗体及其用途
WO2025108394A1 (zh) 抗IL-4Rα抗体或其抗原结合片段及其双特异性抗体和应用
Chen et al. Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody
CN119708224A (zh) 一种抗il-31抗体及其应用
CN120399065A (zh) 抗il-17a纳米抗体、药物组合物、方法及用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ZHEJIANG KANOVA BIOPHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME(S): SUZHOU KANOVA BIOPHARMACEUTICAL CO., LTD.